First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies by Peter Ellmark, Jeffrey Yachnin, Ana Carneiro, Lena Schultz, Amanda Hahn, Sumeet Ambarkhane, Karin Enell Smith, Gustav J. Ullenhag

Get full text

839 Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer by Peter Ellmark, Milad Abolhalaj, Kristina Lundberg, Karin Hägerbrand, Carl Borrebaeck, Viktor Sincic, Henrik Lilljebjörn, Alar Aab, Thoas Fioretos, Fredrik Liedberg

Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T‐cells and regulatory T‐cells in TP53‐mutated acute myeloid leukemia by Milad Abolhalaj, Viktor Sincic, Henrik Lilljebjörn, Carl Sandén, Alar Aab, Karin Hägerbrand, Peter Ellmark, Carl A. K. Borrebaeck, Thoas Fioretos, Kristina Lundberg

Get full text

Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody by Hampus Andersson, Aastha Sobti, David Gomez Jimenez, Yago Pico de Coaña, Sumeet Vijay Ambarkhane, Karin Hägerbrand, Karin Enell Smith, Malin Lindstedt, Peter Ellmark

Get full text

858 A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies by Peter Ellmark, Karin Hägerbrand, Doreen Werchau, Anna Rosén, Karin Barchan, Adnan Deronic, Mattias Levin, Laura Von Schantz, Laura Varas, Anna Säll, Lill Ljug, Mia Thageson, Christina Sakellariou

837 Combination treatment with ATOR-4066, a Neo-X-Prime™ bispecific antibody targeting CD40 and CEACAM5, and anti-PD-1 reverses T cell exhaustion in vitro by Malin Lindstedt, Peter Ellmark, Karin Hägerbrand, Sara Fritzell, Anette Sundstedt, David Gomez Jimenez, Anneli Nilsson, Lill Ljung, Mattias Levin, Mona Celander, Ida Uddbäck, Amulya Krishna Shetty, Hampus Andersson

Distinct Infiltration of T Cell Populations in Bladder Cancer Molecular Subtypes by Viktor Sincic, Ken F. Arlenhold, Sarah Richtmann, Henrik Lilljebjörn, Pontus Eriksson, Gottfrid Sjödahl, Mats Wokander, Karin Hägerbrand, Peter Ellmark, Thoas Fioretos, Carl A. K. Borrebaeck, Fredrik Liedberg, Kristina Lundberg

Get full text

Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy by Maria Georganaki, Mohanraj Ramachandran, Sander Tuit, Nicolás Gonzalo Núñez, Alexandros Karampatzakis, Grammatiki Fotaki, Luuk van Hooren, Hua Huang, Roberta Lugano, Thomas Ulas, Aura Kaunisto, Eric C Holland, Peter Ellmark, Sara M Mangsbo, Joachim Schultze, Magnus Essand, Sonia Tugues, Anna Dimberg

Get full text

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation by Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan, Christina Furebring, Per Norlén, Peter Ellmark

Get full text

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies by Malin Lindstedt, Peter Ellmark, Lennart Greiff, Karin Hägerbrand, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Anna Rosén, Anette Sundstedt, Adnan Deronic, Lill Ljung, Mattias Levin, Laura Varas, Anna Säll, Christina Sakellariou, Barnabas Nyesiga, David Gomez Jimenez, Mona Celander, Deniz Bölükbas, Fredrika Carlsson

Get full text